FDA Clearance Tracker · P990065-S014
SIR-Spheres Y-90 resin microspheres
Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jul 1, 2025
Approved
Time to decision
532 days
Received Jan 16, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P990065-S014
- Device name
- SIR-Spheres Y-90 resin microspheres
- Applicant
- Sirtex Medical, Inc.
- Applicant location
- Woburn, MA
- Received
- Jan 16, 2024
- Decided
- Jul 1, 2025
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P990065
Device type
- Device type
- Microspheres radionuclide (NAW)
- Device class
- Class III
- Specialty
- Radiology & Imaging
FDA's approval statement
As written in FDA's record.
SIR-Spheres® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child Pugh-A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) of FUDR (Floxuridine).
Source documents
Other decisions for Sirtex Medical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P220020 · Decided Apr 4, 2023 · 180 days after receipt
Device type: Embolization Agent, Vascular (QVG) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.